Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,288.30 +6.39 (+0.50%)
Official Closing Price Updated: 6:30 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
News headline image
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock? ↗
In April, regulators approved Foundayo, Eli Lilly's GLP-1 pill for weight loss. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients ↗
Eli Lilly releases positive Phase 3 data for Jaypirca and Retevmo, with trial results supporting potential label expansion. 
Via Benzinga
News headline image
Eli Lilly & Co (NYSE:LLY) Presents a Prime Case for Affordable Growth Investing ↗
Eli Lilly (LLY) exemplifies the GARP strategy with strong growth, reasonable valuation relative to peers, and robust profitability for sustainable returns. 
Via Chartmill
News headline image
3 Mid-Cap Stocks Walking a Fine Line
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
1 Profitable Stock to Own for Decades and 2 That Underwhelm
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
The Post-Ozempic Economy? 2 Industries Bracing for a Slimmer, Less Hungry America ↗
The use of weight-loss drugs is growing like crazy and changing the entire consumer economy along with it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire ↗
And it's not too late to get in on the action. 
Via The Motley Fool
News headline image
Here's Why Buying This Vanguard Index Fund Today Could Be the Best Financial Decision You Ever Make ↗
The Vanguard S&P 500 ETF is a no-brainer for investors seeking more diversification in their portfolio. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Earnings
News headline image
Amazon (AMZN) Stock Trades Up, Here Is Why
What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 4.5% in the afternoon session after CEO Andy Jassy's annual s... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge... 
Via MarketMinute
Topics Economy Supply Chain
News headline image
Eli Lilly Just Launched Its $149 Obesity Pill ↗
Eli Lilly launches Foundayo weight-loss pill after FDA approval, priced from $149/month, as competition with Novo Nordisk intensifies. 
Via Benzinga
News headline image
What to Expect From Eli Lilly's Next Quarterly Earnings Report
Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings. 
Via Barchart.com
Topics ETFs
News headline image
What's Going On With GoodRx Stock Thursday? ↗
GoodRx shares rise after expanding Eli Lilly's GLP-1 access; analysts keep Buy rating ahead of May earnings. 
Via Benzinga
News headline image
Eli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales ↗
Eli Lilly and Co. is facing mounting pressure in India as a surge rise in lower-cost generic alternatives dent sales. 
Via Benzinga
News headline image
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the... 
Via MarketMinute
News headline image
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? ↗
One of these players is well-positioned for market leadership. 
Via The Motley Fool
News headline image
Looks Like M&A Week in 3 Different Sectors ↗
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry. 
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why AC Immune Stock Zoomed Almost 15% Higher Today ↗
It's getting a cash infusion from its giant pharmaceutical partner. 
Via The Motley Fool
News headline image
Great News for Eli Lilly Stock Investors! ↗
The weight loss segment is poised to generate lucrative profits for Eli Lilly. 
Via The Motley Fool
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets MASLD and GLP-1 Imaging Bottleneck With TAEUS® as Stocks Under $5 Gain Attention Inside
Via AB Newswire
News headline image
Is Eli Lilly Stock a Buy After a Brand New Approval? ↗
The stock's dip might be an opportunity. 
Via The Motley Fool
News headline image
The AI Engine: S&P 500 Defies Gravity with 13.3% Q4 Growth as Tech Titans Carry the Weight
The fourth-quarter 2025 earnings season has officially drawn to a close, leaving market analysts and investors in awe of the S&P 500’s resilience. Defying high interest rates and a cooling labor... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects 
Via TheNewswire.com
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.